124 related articles for article (PubMed ID: 38896381)
1. Exploratory Efficacy Evaluation of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: 32-Week Results from a Phase 2, Randomized, Placebo-Controlled Study.
Okubo Y; Terui T; Kobayashi S; Sano S; Morita A; Imafuku S; Tada Y; Abe M; Yaguchi M; Kimura T; Shimauchi J; Zhang W; Amouzadeh H; Murakami M
Dermatol Ther (Heidelb); 2024 Jun; ():. PubMed ID: 38896381
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: Results from a Phase 2, Randomized, Placebo-Controlled Study.
Terui T; Okubo Y; Kobayashi S; Sano S; Morita A; Imafuku S; Tada Y; Abe M; Yaguchi M; Uehara N; Handa T; Tanaka M; Zhang W; Paris M; Murakami M
Am J Clin Dermatol; 2023 Sep; 24(5):837-847. PubMed ID: 37233897
[TBL] [Abstract][Full Text] [Related]
3. Apremilast in Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Meta-analysis.
Spencer RK; Elhage KG; Jin JQ; Davis MS; Hakimi M; Bhutani T; Liao W
Dermatol Ther (Heidelb); 2023 Feb; 13(2):437-451. PubMed ID: 36609960
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Guselkumab in Japanese Patients With Palmoplantar Pustulosis: A Phase 3 Randomized Clinical Trial.
Terui T; Kobayashi S; Okubo Y; Murakami M; Zheng R; Morishima H; Goto R; Kimura T
JAMA Dermatol; 2019 Oct; 155(10):1153-1161. PubMed ID: 31268476
[TBL] [Abstract][Full Text] [Related]
5. A multicentre open-label study of apremilast in palmoplantar pustulosis (APLANTUS).
Wilsmann-Theis D; Kromer C; Gerdes S; Linker C; Magnolo N; Sabat R; Reich K; Mössner R
J Eur Acad Dermatol Venereol; 2021 Oct; 35(10):2045-2050. PubMed ID: 34077577
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the Efficacy and Safety of Apremilast and Methotrexate in Patients with Palmoplantar Psoriasis: A Randomized Controlled Trial.
Kt S; Thakur V; Narang T; Dogra S; Handa S
Am J Clin Dermatol; 2021 May; 22(3):415-423. PubMed ID: 33712987
[TBL] [Abstract][Full Text] [Related]
7. Sustained efficacy and safety of guselkumab in patients with palmoplantar pustulosis through 1.5 years in a randomized phase 3 study.
Okubo Y; Morishima H; Zheng R; Terui T
J Dermatol; 2021 Dec; 48(12):1838-1853. PubMed ID: 34453358
[TBL] [Abstract][Full Text] [Related]
8. Apremilast for the treatment of moderate-to-severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomized study.
Bissonnette R; Haydey R; Rosoph LA; Lynde CW; Bukhalo M; Fowler JF; Delorme I; Gagné-Henley A; Gooderham M; Poulin Y; Barber K; Jenkin P; Landells I; Pariser DM
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):403-410. PubMed ID: 29055155
[TBL] [Abstract][Full Text] [Related]
9. A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis.
Bissonnette R; Maari C; Tsianakas A; Reid D; McCutchan S; Baumgartner S; Mackay J; Bhakta N
Dermatol Ther (Heidelb); 2021 Dec; 11(6):2179-2193. PubMed ID: 34716902
[TBL] [Abstract][Full Text] [Related]
10. Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study.
Burden AD; Bissonnette R; Navarini AA; Murakami M; Morita A; Haeufel T; Ye B; Baehner F; Terui T
Dermatol Ther (Heidelb); 2023 Oct; 13(10):2279-2297. PubMed ID: 37731086
[TBL] [Abstract][Full Text] [Related]
11. Immediate response to apremilast in patients with palmoplantar pustulosis: a retrospective pilot study.
Kato N; Takama H; Ando Y; Yanagishita T; Ohshima Y; Ohashi W; Akiyama M; Watanabe D
Int J Dermatol; 2021 May; 60(5):570-578. PubMed ID: 33454961
[TBL] [Abstract][Full Text] [Related]
12. Oral alitretinoin treatment in patients with palmoplantar pustulosis inadequately responding to standard topical treatment: a randomized phase II study.
Reich K; Graff O; Mehta N
Br J Dermatol; 2016 Jun; 174(6):1277-81. PubMed ID: 26800106
[TBL] [Abstract][Full Text] [Related]
13. Local injection of micro-dose anti-interleukin-17A antibody for palmoplantar pustulosis: A real-world study.
Xia R; Liu J; Gao Y; Diao Z; Chen D; Zhou C; Zhang Z; Yin Z
Clin Immunol; 2023 Aug; 253():109694. PubMed ID: 37433424
[TBL] [Abstract][Full Text] [Related]
14. Comparative evaluation of efficacy and tolerability of apremilast and methotrexate in patients of moderate-to-severe palmoplantar psoriasis: A randomized, parallel, open-label clinical trial.
Wagh M; Mukhi J; Sontakke S; Dhok A; Turankar A; Kalikar M
Indian J Pharmacol; 2023; 55(6):356-362. PubMed ID: 38174531
[TBL] [Abstract][Full Text] [Related]
15. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis.
Bissonnette R; Pariser DM; Wasel NR; Goncalves J; Day RM; Chen R; Sebastian M
J Am Acad Dermatol; 2016 Jul; 75(1):99-105. PubMed ID: 27021239
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic/Pharmacodynamic Analysis of Guselkumab for Treatment of Palmoplantar Pustulosis: Clinical Implications of Guselkumab Dose, Disease Severity, and Smoking in Japanese Patients.
Iwaki Y; Shibata S; Hu C
J Clin Pharmacol; 2022 Feb; 62(2):182-189. PubMed ID: 34382209
[TBL] [Abstract][Full Text] [Related]
17. Etanercept in the treatment of palmoplantar pustulosis.
Bissonnette R; Poulin Y; Bolduc C; Maari C; Provost N; Syrotuik J; Poulin-Costello CM; Nigen S
J Drugs Dermatol; 2008 Oct; 7(10):940-6. PubMed ID: 19112757
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Guselkumab, an Anti-interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis: A Randomized Clinical Trial.
Terui T; Kobayashi S; Okubo Y; Murakami M; Hirose K; Kubo H
JAMA Dermatol; 2018 Mar; 154(3):309-316. PubMed ID: 29417135
[TBL] [Abstract][Full Text] [Related]
19. Treatment of palmoplantar psoriasis with infliximab: a randomized, double-blind placebo-controlled study.
Bissonnette R; Poulin Y; Guenther L; Lynde CW; Bolduc C; Nigen S
J Eur Acad Dermatol Venereol; 2011 Dec; 25(12):1402-8. PubMed ID: 21349113
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
